Section of Medical Oncology

Medicine & Life Sciences

1. Neoplasms 100%
2. Breast Neoplasms 76%
3. Non-Small Cell Lung Carcinoma 73%
4. Survival 63%
5. Therapeutics 61%
6. Drug Therapy 58%
7. Progression-Free Survival 46%
8. Rituximab 44%
9. Hodgkin Disease 32%
10. Mantle-Cell Lymphoma 32%
11. Non-Hodgkin's Lymphoma 31%
12. Mutation 28%
13. Sarcoma 28%
14. Lung Neoplasms 27%
15. Lymphoma, Large B-Cell, Diffuse 27%
16. Radiotherapy 26%
17. Immunotherapy 26%
18. Brentuximab Vedotin 24%
19. Clinical Trials 24%
20. Follicular Lymphoma 24%
21. T-Lymphocytes 24%
22. Lymphoma 24%
23. Triple Negative Breast Neoplasms 23%
24. Neoplasm Metastasis 23%
25. Recurrence 22%
26. Doxorubicin 21%
27. Prostatic Neoplasms 21%
28. Safety 21%
29. Docetaxel 20%
30. Carboplatin 19%
31. Paclitaxel 18%
32. gemcitabine 18%
33. Glioblastoma 18%
34. Proteins 18%
35. Bendamustine Hydrochloride 18%
36. Guidelines 17%
37. Confidence Intervals 17%
38. pembrolizumab 17%
39. Cisplatin 17%
40. B-Cell Lymphoma 17%
41. Adenocarcinoma 16%
42. Circulating Tumor DNA 16%
43. Squamous Cell Carcinoma of Head and Neck 16%
44. Cyclophosphamide 16%
45. Melanoma 16%
46. Genes 16%
47. Small Cell Lung Carcinoma 15%
48. DNA 15%
49. Pancreatic Neoplasms 15%
50. Bevacizumab 15%
51. Biomarkers 15%
52. Transplants 14%
53. Genome 14%
54. Peripheral T-Cell Lymphoma 14%
55. Cetuximab 14%
56. Radiation 14%
57. Carcinoma 14%
58. Squamous Cell Carcinoma 14%
59. Pemetrexed 14%
60. Renal Cell Carcinoma 13%
61. Bortezomib 13%
62. Lenalidomide 13%
63. Estrogen Receptors 13%
64. Breast 12%
65. Maintenance 12%
66. Growth 12%
67. Vincristine 12%
68. B-Cell Chronic Lymphocytic Leukemia 12%
69. Multiple Myeloma 12%
70. Etoposide 12%
71. PCI 32765 12%
72. Platinum 11%
73. Maximum Tolerated Dose 11%
74. Placebos 11%
75. Prednisone 11%
76. Neoadjuvant Therapy 11%
77. 130-nm albumin-bound paclitaxel 11%
78. Stem Cell Transplantation 10%
79. Hormones 10%
80. Erythropoietin Receptors 10%
81. Positron-Emission Tomography 10%
82. Neurofibrosarcoma 10%
83. HIV 10%
84. Stem Cells 10%
85. Population 10%
86. Nivolumab 9%
87. Neutropenia 9%
88. palbociclib 9%
89. ErbB Receptors 9%
90. Colorectal Neoplasms 9%
91. Head and Neck Neoplasms 9%
92. Heterografts 9%
93. Bone Marrow 9%
94. Kenya 9%
95. Everolimus 9%
96. High-Throughput Nucleotide Sequencing 9%
97. Adjuvant Chemotherapy 9%
98. Macrophages 8%
99. Sunitinib 8%
100. DNA Damage 8%